Trials Show Drug Helps Fight Cervical Cancer, Companies Say

  • 📰 WebMD
  • ⏱ Reading Time:
  • 14 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 9%
  • Publisher: 51%

Business News News

Business Business Latest News,Business Business Headlines

TIVDAK (tisotumab vedotin) showed a 33% decrease in the risk of worsening disease or death. The intravenous drug showed an improved objective response rate of 17.8% compared to chemotherapy at 5.2%.

Nov. 2, 2023 -- Drug makers Seagen Inc. and Genmab A/S say Phase 3 trial results show a 30% drop in the“Patients with cervical cancer have few treatment options once their cancer comes back or spreads after initial treatment,” said Ignace B. Vergote, MD, co-founder of European Network of Gynaecological Oncological Trial groups and lead investigator in the clinical trial.

“The trial also measured the disease control rate, which is the percentage of patients who experience complete response, partial response or stable disease,” Fox News wrote. “TIVDAK displayed a 75.9% disease control rate, while chemo showed a 58.2% rate.”

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 709. in BUSİNESS

Business Business Latest News, Business Business Headlines